We investigated the therapeutic potential of Lactobacillus salivarius in colitis mice, and the mice were randomly allocated into three groups with each consisting of 10 mice (n = 10): a control group (CSG), a DSS-induced colitis model group (DSG), and a L. salivarius intervention group (LSG). The intervention group received daily oral administration of L. salivarius for seven consecutive days. Compared to the DSS model group, mice receiving L. salivarius exhibited significantly reduced weight loss, lower DAI scores, lessened colon shortening, and improved histopathological profiles, indicating a substantial reduction in inflammatory damage. Additionally, ITS sequencing revealed that L. salivarius significantly influenced the composition of the intestinal fungal community, decreasing the abundance of pathogenic fungi, such as Candida species, by approximately 40%, and restoring fungal homeostasis by reducing the Basidiomycota/Ascomycota ratio. Moreover, L. salivarius effectively alleviated DSS-induced oxidative stress by lowering serum MDA levels while enhancing the activity of SOD and GSH-Px. Furthermore, the probiotic intervention resulted in 30-40% reduction in pro-inflammatory factors (TNF-α, IL-6, and IL-1β) and an increase in the anti-inflammatory factor IL-10 levels, suggesting a pronounced anti-inflammatory effect. In conclusion, L. salivarius exerts significant protective effects against DSS-induced colitis by modulating the gut fungal community, mitigating oxidative stress, and suppressing inflammatory responses. This study is novel in that few probiotic studies have investigated the impact of L. salivarius on gut fungi in DSS-induced colitis. These findings highlight its potential as a therapeutic candidate for managing inflammatory bowel disease.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
Akiyama, S., Nishijima, S., Kojima, Y., Kimura, M., Ohsugi, M., Ueki, K., Mizokami, M., Hattori, M., Tsuchiya, K., Uemura, N., Kawai, T., Bork, P. and Nagata, N., 2024. Multi-biome analysis identifies distinct gut microbial signatures and their crosstalk in ulcerative colitis and Crohn’s disease. Nature Communications 15(1): 10291. https://doi.org/10.1038/s41467-024-54797-8
Banz, M., Stallmach, A., Gaßler, N., Schulze, P.C., Fritzenwanger, M., Cornely, O., Kurzai, O. and Pletz, M.W., 2024. Fatal pulmonary hemorrhage, pneumothorax and skin necrosis caused by IRIS to an Aspergillus flavus infection in a young patient with metamizole associated agranulocytosis. Infection 52(2): 685-690. https://doi.org/10.1007/s15010-023-02149-x
Chang, L., Wang, C., Peng, J., Song, Y., Zhang, W., Chen, Y., Peng, Q., Li, X., Liu, X. and Lan, Y., 2024. Rattan pepper polysaccharide regulates DSS-induced intestinal inflammation and depressive behavior through microbiota-gut-brain axis. Journal of Agricultural and Food Chemistry 72(1): 437-448. https://doi.org/10.1021/acs.jafc.3c08462
Cheng, J., Zhang, Y., Ma, L., Du, W., Zhang, Q., Gao, R., Zhao, X., Chen, Y., Jiang, L., Li, X., Li, B. and Zhou, Y., 2023. Macrophage-derived extracellular vesicles-coated palladium nanoformulations modulate inflammatory and immune homeostasis for targeting therapy of ulcerative colitis. Advanced Science 10(33): e2304002. https://doi.org/10.1002/advs.202304002
Chu, X.-Q., Wang, J., Chen, G.-X., Zhang, G.-Q., Zhang, D.-Y. and Cai, Y.-Y., 2018. Overexpression of microRNA-495 improves the intestinal mucosal barrier function by targeting STAT3 via inhibition of the JAK/STAT3 signaling pathway in a mouse model of ulcerative colitis. Pathology – Research and Practice 214(1): 151-162. https://doi.org/10.1016/j.prp.2017.10.003
Fumery, M., Singh, S., Dulai, P.S., Gower-Rousseau, C., Peyrin-Biroulet, L. and Sandborn, W.J., 2018. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clinical Gastroenterology and Hepatology 16(3): 343-356.e3. https://doi.org/10.1016/j.cgh.2017.06.016
Gu, P., Liu, R., Yang, Q., Xie, L., Wei, R., Li, J., Mei, F., Chen, T., Zeng, Z., He, Y., Zhou, H., Peng, H., Nandakumar, K.S., Chu, H., Jiang, Y., Gong, W., Chen, Y., Schnabl, B. and Chen, P., 2023. A metabolite from commensal Candida albicans enhances the bactericidal activity of macrophages and protects against sepsis. Cellular and Molecular Immunology 20(10): 1156-1170. https://doi.org/10.1038/s41423-023-01070-5
Guo, H., Guo, H., Xie, Y., Chen, Y., Lu, C., Yang, Z., Zhu, Y., Ouyang, Y., Zhang, Y. and Wang, X., 2022. Mo(3)Se(4) nanoparticle with ROS scavenging and multi-enzyme activity for the treatment of DSS-induced colitis in mice. Redox Biology 56: 102441. https://doi.org/10.1016/j.redox.2022.102441
Guo, P., Wang, W., Xiang, Q., Pan, C., Qiu, Y., Li, T., Wang, D., Ouyang, J., Jia, R., Shi, M., Wang, Y., Li, J., Zou, J., Zhong, Y., Zhao, J., Zheng, D., Cui, Y., Ma, G. and Wei, W., 2024. Engineered probiotic ameliorates ulcerative colitis by restoring gut microbiota and redox homeostasis. Cell Host Microbe 32(9): 1502-1518.e9. https://doi.org/10.1016/j.chom.2024.07.028
Herrlinger, K.R. and Stange, E.F., 2023. Prioritization in inflammatory bowel disease therapy. Expert Review of Gastroenterology and Hepatology 17(8): 753-767. https://doi.org/10.1080/17474124.2023.2240699
Huang, X., Hu, M., Sun, T., Li, J., Zhou, Y., Yan, Y., Xuan, B., Wang, J., Xiong, H., Ji, L., Zhu, X., Tong, T., Ning, L., Ma, Y., Zhao, Y., Ding, J., Guo, Z., Zhang, Y., Fang, J.-Y., Hong, J. and Chen, H., 2023. Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts. Cell Host Microbe 31(11): 1930-1943.e4. https://doi.org/10.1016/j.chom.2023.10.005
Landskron, G., Dubois-Camacho, K., Orellana-Serradell, O., De la Fuente, M., Parada-Venegas, D., Bitrán, M., Diaz-Jimenez, D., Tang, S., Cidlowski, J.A., Li, X., Molina, H., Gonzalez, C.M., Simian, D., Lubascher, J., Pola, V., Montecino, M., Blokzijl, T., Faber, K.N., González, M.-J., Quera, R. and Hermoso, M.A., 2022. Regulation of the intestinal extra-adrenal steroidogenic pathway component LRH-1 by glucocorticoids in ulcerative colitis. Cells 11(12): 1905. https://doi.org/10.3390/cells11121905
Li, X.V., Leonardi, I., Putzel, G.G., Semon, A., Fiers, W.D., Kusakabe, T., Lin, W.-Y., Gao, I.H., Doron, I., Gutierrez-Guerrero, A., DeCelie, M.B., Carriche, G.M., Mesko, M., Yang, C., Naglik, J.R., Hube, B., Scherl, E.J. and Iliev, I.D., 2022. Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature 603: 672-678. https://doi.org/10.1038/s41586-022-04502-w
Li, Y.-Y., Wang, X.-J., Su, Y.-L., Wang, Q., Huang, S.-W., Pan, Z.-F., Chen, Y.-P., Liang, J.-J., Zhang, M.-L., Xie, X.-Q., Wu, Z.-Y., Chen, J.-Y., Zhou, L. and Luo, X., 2022. Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s. Acta Pharmacologica Sinica 43(6): 1495-1507. https://doi.org/10.1038/s41401-021-00781-7
Lian, L., Zhang, S., Yu, Z., Ge, H., Qi, S., Zhang, X., Long, L., Xiong, X., Chu, D., Ma, X., Li, X. and Gao, H., 2019. The dietary freeze-dried fruit powder of Actinidia arguta ameliorates dextran sulphate sodium-induced ulcerative colitis in mice by inhibiting the activation of MAPKs. Food and Function 10(9): 5768-5778. https://doi.org/10.1039/c9fo00664h
Meng, A., Zhang, X., Pubu, P., Ali, M., Wang, J., Xu, C., Almutairi, M.H. and Li, K., 2024. Protective effect of lentinan against LPS-induced injury in mice via influencing antioxidant enzyme activity, inflammatory pathways and gut microbiota. Pakistan Veterinary Journal 44(3): 647-656. https://doi.org/10.29261/pakvetj/2024.225
Peng, S., Xu, C., He, Q., Xu, J., Kiani, F.A., Choudhary, O.P., Idrees, A., Mares, M.M., Wu, Y. and Li, K., 2024. Fucoidan alleviates intestine damage in mice induced by LPS via regulation of microbiota. Pakistan Veterinary Journal 44(2): 517-525. http://dx.doi.org/10.29261/pakvetj/2024.190
Pourjafar, H., Ansari, F., Sadeghi, A., Samakkhah, S.A. and Jafari, S.M., 2023. Functional and health-promoting properties of probiotics’ exopolysaccharides; isolation, characterization and applications in the food industry. Critical Reviews in Food Science and Nutrition 63(26): 8194-8225. https://doi.org/10.1080/10408398.2022.2047883
Steiger, S., Marcucci, V., Desai, V., Zheng, M. and Parker, G., 2022. Refractory fulminant colitis requiring surgical intervention in a patient with ulcerative colitis on atezolizumab therapy for small cell lung cancer: an atypical case. Cureus 14(5): e25437. https://doi.org/10.7759/cureus.25437
Wang, N., Xiang, Y., Ma, Y., Zhang, P., Zhou, X., Zhu, H., Zhang, Z., Li, Z., Xiao, X., He, M., Mehmood, M.A. and Zhu, H., 2024. Fermented Spirulina platensis alleviated DSS-induced ulcerative colitis by regulating gut microbiota and MyD88/TLR4 signaling pathway. Asian Journal of Agriculture and Biology 2024(1): 2023232. https://doi.org/10.35495/ajab.2023.232
Wu, Y., Ran, L., Yang, Y., Gao, X., Peng, M., Liu, S., Sun, L., Wan, J., Wang, Y., Yang, K., Yin, M. and Chunyu, W., 2023. Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota. Life Sciences 314: 121312. https://doi.org/10.1016/j.lfs.2022.121312
Zeng, S., Rosati, E., Saggau, C., Messner, B., Chu, H., Duan, Y., Hartmann, P., Wang, Y., Ma, S., Huang, W.J.M., Lee, J., Lee, S.M., Carvalho-Gontijo, R., Zhang, V., Hoffmann, J.P., Kolls, J.K., Raz, E., Brenner, D.A., Kisseleva, T., LeibundGut-Landmann, S., Bacher, P., Stärkel, P. and Schnabl, B., 2023. Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe 31(3): 389-404.e7. https://doi.org/10.1016/j.chom.2023.02.001
Zhou, J., Li, M., Chen, Q., Li, X., Chen, L., Dong, Z., Zhu, W., Yang, Y., Liu, Z. and Chen, Q., 2022. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. Nature Communications 13(1): 3432. https://doi.org/10.1038/s41467-022-31171-0
| 全部期间 | 过去一年 | 过去30天 | |
|---|---|---|---|
| 摘要浏览次数 | 131 | 131 | 28 |
| 全文浏览次数 | 3 | 3 | 0 |
| PDF下载次数 | 6 | 6 | 0 |
We investigated the therapeutic potential of Lactobacillus salivarius in colitis mice, and the mice were randomly allocated into three groups with each consisting of 10 mice (n = 10): a control group (CSG), a DSS-induced colitis model group (DSG), and a L. salivarius intervention group (LSG). The intervention group received daily oral administration of L. salivarius for seven consecutive days. Compared to the DSS model group, mice receiving L. salivarius exhibited significantly reduced weight loss, lower DAI scores, lessened colon shortening, and improved histopathological profiles, indicating a substantial reduction in inflammatory damage. Additionally, ITS sequencing revealed that L. salivarius significantly influenced the composition of the intestinal fungal community, decreasing the abundance of pathogenic fungi, such as Candida species, by approximately 40%, and restoring fungal homeostasis by reducing the Basidiomycota/Ascomycota ratio. Moreover, L. salivarius effectively alleviated DSS-induced oxidative stress by lowering serum MDA levels while enhancing the activity of SOD and GSH-Px. Furthermore, the probiotic intervention resulted in 30-40% reduction in pro-inflammatory factors (TNF-α, IL-6, and IL-1β) and an increase in the anti-inflammatory factor IL-10 levels, suggesting a pronounced anti-inflammatory effect. In conclusion, L. salivarius exerts significant protective effects against DSS-induced colitis by modulating the gut fungal community, mitigating oxidative stress, and suppressing inflammatory responses. This study is novel in that few probiotic studies have investigated the impact of L. salivarius on gut fungi in DSS-induced colitis. These findings highlight its potential as a therapeutic candidate for managing inflammatory bowel disease.
| 全部期间 | 过去一年 | 过去30天 | |
|---|---|---|---|
| 摘要浏览次数 | 131 | 131 | 28 |
| 全文浏览次数 | 3 | 3 | 0 |
| PDF下载次数 | 6 | 6 | 0 |